Treatment of sexual dysfunction
First Claim
Patent Images
1. A method of treating sexual dysfunction which comprises administering to a subject suffering therefrom and in need of treatment an effective amount of a bombesin receptor antagonist.
1 Assignment
0 Petitions
Accused Products
Abstract
Bombesin receptor antagonists have been found to be useful in the treatment of sexual dysfunction in both males and females. They may be selective BB1 antagonists or mixed BB1/BB2 antagonists. Combinations are disclosed of bombesin receptor antagonists with a range of other active compounds, for example PDE5 inhibitors, NEP inhibitors and lasofoxifene.
51 Citations
67 Claims
- 1. A method of treating sexual dysfunction which comprises administering to a subject suffering therefrom and in need of treatment an effective amount of a bombesin receptor antagonist.
-
35. A method of treating sexual dysfunction in a male or female subject suffering therefrom and in need of treatment which comprises administering to the subject an effective amount of a bombesin receptor antagonist and a PDE 5 inhibitor.
-
36. A method of treating sexual dysfunction in a male or female subject suffering therefrom and in need of treatment which comprises administering to the subject an effective amount of a bombesin receptor antagonist and a NEP inhibitor.
-
37. A method of treating sexual dysfunction in a female subject suffering therefrom and in need of treatment which comprises administering to the subject an effective amount of a bombesin receptor antagonist and one or more estrogen receptor modulators (SERM) and/or estrogen agonists and/or estrogen antagonists.
-
38. A method of treating sexual dysfunction in a male or female subject suffering therefrom and in need of treatment which comprises administering to the subject an effective amount of a bombesin receptor antagonist and lasofoxifene.
-
39. A pharmaceutical combination (for simultaneous, separate or sequential administration) of a bombesin receptor antagonist and one or more materials selected from (1) to (34) below:
-
(1) naturally occurring or synthetic prostaglandins or esters thereof;
(2) α
-adrenergic receptor antagonist compounds also known as α
-adrenoceptor antaginists or α
-receptor antagonists or α
-blockers;
(3) NO-donor (NO-agonist) compounds;
(4) potassium channel openers or modulators;
(5) dopaminergic agents;
(6) vasodilator agents;
(7) thromboxane A2 agonists;
(8) CNS active agents;
(9) ergot alkaloids;
(10) compounds which modulate the action of natriuretic factors;
(11) angiotensin receptor antagonists such as losartan.;
(12) substrates for NO-synthase;
(13) calcium channel blockers;
(14) cholesterol lowering agents;
(15) antiplatelet and antithrombotic agents;
(16) insulin sensitising agents and hypoglycaemic agents;
.(17) L-DOPA or carbidopa;
(18) acetylcholinesterase inhibitors;
(19) steroidal or non-steroidal anti-inflammatory agents;
(20) estrogen receptor modulators and/or estrogen agonists and/or estrogen antagonists, and pharmaceutically acceptable salts thereof;
(21) PDE inhibitors;
(22) NPY (neuropeptide Y) inhibitors;
(23) NEP inhibitors;
(24) vasoactive intestinal proteins (VIP), VIP mimetics, VIP analogues, VIP receptor agonists or VIP analogues or VIP fragments, or α
-adrenoceptor antagonists with VIP combinations;
(25) melanocortin receptor agonists or modulators or melanocortin ehancers;
(26) serotonin receptor agonists, antagonists or modulators;
(27) testosterone replacement agents, testosternone, dihydrotestosterone or a testosterone implant;
(28) estrogen, estrogen and medroxyprogesterone or medroxyprogesterone acetate (MPA) (i.e. as a combination), or estrogen and methyl testosterone hormone replacement therapy agents;
(29) modulators of transporters for noradrenaline, dopamine and/or serotonin;
(30) purinergic receptor agonists and/or modulators;
(31) neurokinin (NK) receptor antagonists;
(32) opioid receptor agonists, antagonista or modulators;
(33) agonists or modulators for oxytocin/vasopressin receptors; and
(34) modulators of cannabinoid receptors.
-
-
64. A pharmaceutical combination (for simultaneous, separate or sequential administration) of a bombesin receptor antagonist and a PDE 5 inhibitor.
-
65. A pharmaceutical combination (for simultaneous, separate or sequential administration) of a bombesin receptor antagonist and a NEP inhibitor.
-
66. A pharmaceutical combination (for simultaneous, separate or sequential administration) of a bombesin receptor antagonist and one or more estrogen receptor modulators (SERM) and/or estrogen agonists and/or estrogen antagonists.
-
67. A pharmaceutical combination (for simultaneous, separate or sequential administration) of a bombesin receptor antagonist and lasofoxifene.
Specification